PDF(Pubmed)
Abstract：
UNASSIGNED: Uncaria tomentosa (Willd. ex Schult.) DC. (Rubiaceae) is traditionally used by Amazonian indigenous groups to treat inflammatory diseases. To date, there are no systematic reviews and meta-analyses on the use of U. tomentosa for inflammation control in animals supporting the traditional knowledge about this species. This study was conducted to evaluate the effect of U. tomentosa extracts in modulating inflammatory mediators and to determine which types of inflammatory diseases can be treated by this species.
UNASSIGNED: We conducted a systematic review and meta-analysis of preclinical studies published before 26 July 2023, identified in PubMed, Embase, and Scopus. Four independent reviewers extracted the data and assessed the risks of bias. The effects of U. tomentosa on inflammatory diseases and the inflammatory mediators involved were extracted from the studies. Standardized mean differences (SMD) and 95% confidence intervals (95%CI) of the outcomes were estimated. The meta-analyses were conducted using RevMan 5.4 (Cochrane Collaboration). This protocol was registered in PROSPERO (CRD42023450869).
UNASSIGNED: Twenty-four of 523 studies were included. U. tomentosa extracts decreased the cytokines interleukin (IL)-6 (SMD: -0.72, 95%CI: -1.15, -0.29, p = 0.001) and transcription factor nuclear factor kappa-B (NF-κB) (SMD: -1.19, 95%CI: -1.89, -0.48, p = 0.001). However, the extracts did not significantly alter IL-1 (SMD: -0.16, 95%CI: -0.87, +0.56, p = 0.67), IL-10 (SMD: -0.05, 95%CI:-0.35, 0.45, p = 0.80), or tumor necrosis factor-alpha (TNF-α) levels (SMD: 0.18, 95%CI: -0.25, 0.62, p = 0.41).
UNASSIGNED: Many extracts of stem bark, roots, and leaves of U. tomentosa, mostly aqueous and hydroethanolic, exhibited anti-inflammatory and/or immunomodulatory activities and low toxicity. The extracts decreased NF-κB and IL-6. These findings suggest that this species has the potential to treat inflammatory diseases in which these markers are increased, according to the ethnopharmacological use. These activities are not related to a specific class of compounds.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=450869, Identifier CRD42023450869.
UNASSIGNED: We conducted a systematic review and meta-analysis of preclinical studies published before 26 July 2023, identified in PubMed, Embase, and Scopus. Four independent reviewers extracted the data and assessed the risks of bias. The effects of U. tomentosa on inflammatory diseases and the inflammatory mediators involved were extracted from the studies. Standardized mean differences (SMD) and 95% confidence intervals (95%CI) of the outcomes were estimated. The meta-analyses were conducted using RevMan 5.4 (Cochrane Collaboration). This protocol was registered in PROSPERO (CRD42023450869).
UNASSIGNED: Twenty-four of 523 studies were included. U. tomentosa extracts decreased the cytokines interleukin (IL)-6 (SMD: -0.72, 95%CI: -1.15, -0.29, p = 0.001) and transcription factor nuclear factor kappa-B (NF-κB) (SMD: -1.19, 95%CI: -1.89, -0.48, p = 0.001). However, the extracts did not significantly alter IL-1 (SMD: -0.16, 95%CI: -0.87, +0.56, p = 0.67), IL-10 (SMD: -0.05, 95%CI:-0.35, 0.45, p = 0.80), or tumor necrosis factor-alpha (TNF-α) levels (SMD: 0.18, 95%CI: -0.25, 0.62, p = 0.41).
UNASSIGNED: Many extracts of stem bark, roots, and leaves of U. tomentosa, mostly aqueous and hydroethanolic, exhibited anti-inflammatory and/or immunomodulatory activities and low toxicity. The extracts decreased NF-κB and IL-6. These findings suggest that this species has the potential to treat inflammatory diseases in which these markers are increased, according to the ethnopharmacological use. These activities are not related to a specific class of compounds.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=450869, Identifier CRD42023450869.
摘要：
■钩藤（威尔德。前Schult.)DC。（Rubiaceae）传统上被亚马逊土著群体用来治疗炎症性疾病。迄今为止,目前还没有系统评价和荟萃分析,以支持有关该物种的传统知识,对使用绒毛膜孢菌控制动物炎症进行研究.进行这项研究是为了评估毛霉素提取物在调节炎症介质中的作用，并确定该物种可以治疗哪种类型的炎性疾病。
■我们对2023年7月26日之前发表的临床前研究进行了系统评价和荟萃分析，Embase,还有Scopus.四名独立审稿人提取了数据并评估了偏见的风险。从研究中提取了绒毛膜下对炎性疾病的影响以及所涉及的炎症介质。估计结果的标准化平均差异（SMD）和95％置信区间（95CI）。荟萃分析使用RevMan5.4(CochraneCollaboration)进行。该协议在PROSPERO(CRD42023450869)中注册。
■纳入了523项研究中的24项。绒毛乳杆菌提取物降低细胞因子白细胞介素（IL）-6（SMD：-0.72，95CI：-1.15，-0.29，p=0.001）和转录因子核因子κB（NF-κB）（SMD：-1.19，95CI：-1.89，-0.48，p=0.001）。然而,提取物没有显著改变IL-1(SMD:-0.16,95CI:-0.87,+0.56,p=0.67),IL-10（SMD：-0.05，95CI：-0.35，0.45，p=0.80），或肿瘤坏死因子-α（TNF-α）水平（SMD：0.18，95CI：-0.25，0.62，p=0.41）。
■许多茎皮提取物，根,和毛霉的叶子，主要是水性和乙醇，表现出抗炎和/或免疫调节活性和低毒性。提取物降低NF-κB和IL-6。这些发现表明，该物种具有治疗这些标志物增加的炎症性疾病的潜力，根据民族药理学使用。这些活性与特定类别的化合物无关。
系统审查注册：https://www。crd.约克。AC.uk/prospro/display_record.php?RecordID=450869，标识符CRD42023450869。
■我们对2023年7月26日之前发表的临床前研究进行了系统评价和荟萃分析，Embase,还有Scopus.四名独立审稿人提取了数据并评估了偏见的风险。从研究中提取了绒毛膜下对炎性疾病的影响以及所涉及的炎症介质。估计结果的标准化平均差异（SMD）和95％置信区间（95CI）。荟萃分析使用RevMan5.4(CochraneCollaboration)进行。该协议在PROSPERO(CRD42023450869)中注册。
■纳入了523项研究中的24项。绒毛乳杆菌提取物降低细胞因子白细胞介素（IL）-6（SMD：-0.72，95CI：-1.15，-0.29，p=0.001）和转录因子核因子κB（NF-κB）（SMD：-1.19，95CI：-1.89，-0.48，p=0.001）。然而,提取物没有显著改变IL-1(SMD:-0.16,95CI:-0.87,+0.56,p=0.67),IL-10（SMD：-0.05，95CI：-0.35，0.45，p=0.80），或肿瘤坏死因子-α（TNF-α）水平（SMD：0.18，95CI：-0.25，0.62，p=0.41）。
■许多茎皮提取物，根,和毛霉的叶子，主要是水性和乙醇，表现出抗炎和/或免疫调节活性和低毒性。提取物降低NF-κB和IL-6。这些发现表明，该物种具有治疗这些标志物增加的炎症性疾病的潜力，根据民族药理学使用。这些活性与特定类别的化合物无关。
系统审查注册：https://www。crd.约克。AC.uk/prospro/display_record.php?RecordID=450869，标识符CRD42023450869。
